Mycoplasma pneumoniae Clinical Manifestations, Microbiology, and Immunology
Mycoplasma pneumoniae (Mp) is a major human pathogen that causes both upper and lower respiratory infections, and is one of the leading causes of community acquired pneumonia (CAP), accounting for 11-15% of CAP throughout the world. Additionally it is known to induce an inflammatory process which de...
Format: | eBook |
---|---|
Language: | English |
Published: |
Frontiers Media SA
2017
|
Series: | Frontiers Research Topics
|
Subjects: | |
Online Access: | Open Access: DOAB: description of the publication Open Access: DOAB, download the publication |
LEADER | 03161namaa2200493uu 4500 | ||
---|---|---|---|
001 | doab54175 | ||
003 | oapen | ||
005 | 20210211 | ||
006 | m o d | ||
007 | cr|mn|---annan | ||
008 | 210211s2017 xx |||||o ||| 0|eng d | ||
020 | |a 978-2-88945-362-7 | ||
020 | |a 9782889453627 | ||
024 | 7 | |a 10.3389/978-2-88945-362-7 |2 doi | |
040 | |a oapen |c oapen | ||
041 | 0 | |a eng | |
042 | |a dc | ||
072 | 7 | |a M |2 bicssc | |
720 | 1 | |a Takashi Shimizu |4 aut | |
720 | 1 | |a Annemarie Van Rossum |4 aut | |
720 | 1 | |a Cecile Bebear |4 aut | |
720 | 1 | |a Ran Nir-Paz |4 aut | |
720 | 1 | |a Takeshi Saraya |4 aut | |
245 | 0 | 0 | |a Mycoplasma pneumoniae Clinical Manifestations, Microbiology, and Immunology |
260 | |b Frontiers Media SA |c 2017 | ||
300 | |a 1 online resource (175 p.) | ||
336 | |a text |b txt |2 rdacontent | ||
337 | |a computer |b c |2 rdamedia | ||
338 | |a online resource |b cr |2 rdacarrier | ||
490 | 1 | |a Frontiers Research Topics | |
506 | 0 | |a Open Access |f Unrestricted online access |2 star | |
520 | |a Mycoplasma pneumoniae (Mp) is a major human pathogen that causes both upper and lower respiratory infections, and is one of the leading causes of community acquired pneumonia (CAP), accounting for 11-15% of CAP throughout the world. Additionally it is known to induce an inflammatory process which depends on several mechanisms such as virulence of Mp (lipoproteins, community acquired respiratory distress syndrome (CARDS) toxin, oxidative products) and host defenses (cellular immunity and humoral immunity). Although it is a common pathogen, the pathogenesis for Mp infections is not yet fully understood. From the clinical point of view, since the pioneer studies in the 1960s and 1970s on the clinical presentation of Mp associated disease, the diagnostics approaches have changed dramatically leading to a better understanding of the clinical presentation and new issues have emerged - such as antibiotics resistance. The purpose of this Frontiers ebook is to thoroughly review and discuss the clinical presentation in view of the improved diagnostics, microbiological and immunological analysis of Mp infections, with focus on the history of Mp, clinical features of disease, bacterial structure of Mp and mechanism of gliding, clinical and laboratory diagnostics, the role of lipoproteins and Toll-like receptor, CARDS toxin, subtyping of Mp isolates and genome analysis, macrolide resistance and treatment. | ||
540 | |a Creative Commons |f https://creativecommons.org/licenses/by/4.0/ |2 cc |u https://creativecommons.org/licenses/by/4.0/ | ||
546 | |a English | ||
650 | 7 | |a Medicine |2 bicssc | |
653 | |a clinical presentation antimicrobial resistance | ||
653 | |a epidemiology | ||
653 | |a Mycoplasma pneumoniae | ||
653 | |a outcome | ||
653 | |a pathogenesis | ||
653 | |a treatment | ||
793 | 0 | |a DOAB Library. | |
856 | 4 | 0 | |u https://directory.doabooks.org/handle/20.500.12854/54175 |7 0 |z Open Access: DOAB: description of the publication |
856 | 4 | 0 | |u https://www.frontiersin.org/research-topics/3925/mycoplasma-pneumoniae-clinical-manifestations-microbiology-and-immunology |7 0 |z Open Access: DOAB, download the publication |